Merck & Co Inc (MRK) Quote| Reuters.com
Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

55.88USD
24 Jun 2016
Change (% chg)

$-1.80 (-3.12%)
Prev Close
$57.68
Open
$56.04
Day's High
$57.07
Day's Low
$55.77
Volume
17,258,559
Avg. Vol
8,965,052
52-wk High
$60.07
52-wk Low
$45.69

MRK

Chart for MRK

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment... (more)

Overall

Beta: 0.67
Market Cap(Mil.): $154,677.30
Shares Outstanding(Mil.): 2,768.02
Dividend: 0.46
Yield (%): 3.29

Financials

  MRK Industry Sector
P/E (TTM): 34.19 32.69 34.11
EPS (TTM): 1.63 -- --
ROI: 5.49 15.00 14.23
ROE: 10.08 16.08 15.46

Roche CEO 'sleeps better' as risk to drugmaker's growth recedes

LONDON Roche is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker's older cancer medicines start to grab business next year, its chief executive said on Wednesday.

Jun 22 2016

BRIEF-Merck announces results of study of Relebactam, in combination with Imipenem/Cilastatin

* Phase 2 study of Relebactam, in combination with Imipenem/Cilastatin for complicated urinary tract infections met primary endpoint

Jun 20 2016

Merck's Keytruda prolongs life in big lung-cancer study

Advanced lung cancer patients who took Merck & Co Inc's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday.

Jun 16 2016

UPDATE 1-Merck's Keytruda prolongs life in big lung-cancer study

June 16 Advanced lung cancer patients who took Merck & Co Inc's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday.

Jun 16 2016

Merck's Keytruda prolongs life in big lung-cancer study

June 16 Advanced lung cancer patients who took Merck & Co's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday.

Jun 16 2016

BRIEF-Merck's Keytruda shows superior progression-free, overall survival in lung cancer patients

* Merck's keytruda (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer

Jun 16 2016

U.S. panel backs approval for Merck infectious diarrhea drug

Merck & Co's experimental drug to treat the most common cause of hospital-associated infectious diarrhea warrants approval, an advisory panel to the U.S. Food and Drug Administration said on Thursday.

Jun 09 2016

BRIEF-Merck to acquire Afferent Pharmaceuticals

* Signed a definitive agreement under which Merck will acquire Afferent Pharmaceuticals

Jun 09 2016

BRIEF-Agenus announces lead product candidate selection in Merck collaboration

* Agenus announces lead product candidate selection in its collaboration with Merck

Jun 09 2016

Gilead escapes liability in hepatitis C patent fight with Merck

NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni.

Jun 07 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.